VJHemOnc Podcast

Novel combinations work well for many patients suffering from chronic lymphocytic leukemia (CLL), but there is a subset of patients who have limited responses to novel agents such as ibrutinib and rituximab. A better option for treatment may be CAR-T cell therapy. This treatment has the potential to treat patients with refractory CLL as well as those in earlier lines of therapy. Increasing evidence has shown that CAR T-cell therapy could be favored over existing therapies due to its short treatment duration and high rates of measurable residual disease (MRD) negativity. Furthermore, CAR-T cells resulted in more tolerable toxicities than novel combinations. There is increasing optimism that CAR-T will be integrated into the CLL treatment landscape.

In this podcast, Saar Gill, MD, PhD, University of Pennsylvania, Philadelphia, PA, chairs a debate with Tanya Siddiqi, MD, City of Hope, Duarte, CA, and Jordan Gauthier, MD, Fred Hutchinson Cancer Research Centre, Seattle, WA, in a discussion on CAR-T cell therapy in chronic lymphocytic leukemia (CLL), in the era of venetoclax, ibrutinib, rituximab, and novel combinations.

The post CAR-T in the CLL space appeared first on VJHemOnc.

CAR-T cell therapy offers a potentially paradigm-changing new treatment for multiple myeloma. Additionally, CAR-T toxicity is may be more manageable than other treatments. While cytokine release syndrome (CRS) is common in CAR-T trials, these are generally short-lived and managed with standard therapies. There are various ongoing clinical trials using CAR-T cell technology to target myeloma antigens, and this podcast discusses the use of B-cell maturation antigen (BCMA) CAR-T.

In this podcast, Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, chairs a discussion with Edward Stadtmauer, MD, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, and Krina Patel, MD, MSc, MD Anderson Cancer Center, Houston, TX, on the potential of CAR-T therapy in the treatment of multiple myeloma.

The post CAR T-cell therapy & multiple myeloma: past, present & future appeared first on VJHemOnc.

A deeper understanding of the characteristics, features and interactions at play in the tumor microenvironment has given great insight into the pathogenesis of lymphoma, and contributed to the identification of novel therapeutic targets. The interaction between tumor genetics and microenvironment composition could give rise to novel combination strategies. Increasing focus has been put on non-malignant cells residing in the tumor, primarily immune and stromal cells, which form the tumor microenvironment. This has provided the justification for new clinical studies and therefore the opportunity to address unmet clinical needs in lymphoma.

In today’s podcast, Laura Pasqualucci, MD, Columbia University, New York, NY, chairs a discussion with Robert Kridel, MD, MPH, PhD, Princess Margaret Cancer Centre, Toronto, ON, and Nathan Fowler, MD, University of Texas MD Anderson Cancer Centre, Houston, TX, on the tumor microenvironment in lymphoma.

The post Harnessing the tumor microenvironment in lymphoma therapy appeared first on VJHemOnc.

Recent clinical trials studying novel therapeutic strategies to target chronic lymphocytic leukemia (CLL) have brought a spotlight to their potential as alternatives to traditional chemotherapy. Here we bring you an overview and discussion on the latest trial updates, including CLL12, CLL14, RESONATE, ASCEND, among others.

This podcast features Patrick Thornton from Beaumont Hospital, Dublin; Petra Langerbeins of the University of Cologne, Germany; Alessandra Tedeschi from Niguarda Cancer Center, Milan, Italy; Susan O’Brien of the University of California; Paolo Ghia of Università Vita-Salute San Raffaele, Milan, Italy; Othman Al-Sawaf of University Hospital Cologne, Germany; Arnon Kater from the University of Amsterdam; and Tanya Siddiqi of the City of Hope, California. The footage featured is from the European Hematology Association (EHA) 2019, held in Amsterdam, The Netherlands, and the International Conference on Malignant Lymphoma (ICML) 2019 in Lugano, Switzerland.

The post CLL therapy: the latest trial updates and innovative novel therapies for the future appeared first on VJHemOnc.

Despite marked progress in the lymphoma treatment landscape, the prognosis of patients with relapsed and/or refractory disease remains poor; thus, a continued need exists for the development of innovative approaches and therapies. Epigenetic dysregulation may drive and/or promote tumorigenesis in various malignancies and is prevalent in both B-cell and T-cell lymphomas. Over the past decade, a large number of epigenetic-modifying agents have been developed and introduced into the clinical management of patients with hematological malignancies. This podcast features Ari Melnick, MD, of the Weill Cornell Medical College, New York, NY. The footage included is from the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

The post Precision epigenetic therapy for B-cell lymphoma appeared first on VJHemOnc.